Evidence map›Paper›PMID 40229540›Full record

ArticlePsychopharmacology2025

Behavioural effects of oral cannabidiol (CBD) treatment in the superoxide dismutase 1 G93 A (SOD1

Sandip Ghimire, Fabian Kreilaus, Rossana Rosa Porto, Lyndsey L Anderson, Justin J Yerbury, Jonathon C Arnold, Tim Karl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandip Ghimire *School of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.
Fabian Kreilaus *School of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.
Rossana Rosa PortoSchool of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia.
Lyndsey L AndersonLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Justin J YerburyIllawarra Health and Medical Research Institute, Wollongong, NSW, Australia.
Jonathon C ArnoldLambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.
Tim KarlSchool of Medicine, Western Sydney University, Campbelltown, NSW, 2560, Australia. t.karl@westernsydney.edu.au.ORCID http://orcid.org/0000-0001-9904-8482

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting voluntary muscle movement as well as cognitive and other behavioural domains at later disease stages. No effective treatment for ALS is currently available. Elevated neuroinflammation, oxidative stress and alterations to the endocannabinoid system are evident in ALS. The phytocannabinoid cannabidiol (CBD) has anti-inflammatory and anti-oxidant properties. Thus, we evaluated the remedial effects of chronic oral cannabidiol (CBD) treatment on ALS-relevant behavioural domains in the copper-zinc superoxide dismutase 1 (SOD1) mouse model of ALS that carries a G93A mutation (SOD1

methodsMale and female SOD1

resultsCBD treatment ameliorated the bodyweight loss in female SOD1

conclusionThus, the current remedial oral dose of CBD delayed disease progression (inferred by bodyweight) in both male and female mice and improve specific cognitive deficits of SOD1

Indexed as

Amyotrophic Lateral SclerosisBehavior, AnimalCannabidiolAdministration, OralAnimalsDisease Models, AnimalFearFemaleMaleMiceMice, Inbred C57BLMice, TransgenicMotor ActivityPrepulse InhibitionSocial BehaviorSuperoxide DismutaseCannabidiolSOD1 G93A proteinSuperoxide DismutaseSuperoxide Dismutase-1Amyotrophic lateral sclerosisBehaviourCannabidiolCannabinoid therapyOral treatmentSOD1 G93A transgenic mouse model

Identifiers

PMID40229540
PMCPMC12380930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.